Ribo reicht einen Antrag auf eine europäische klinische Studie der Phase I für die gegen INHBE gerichtete siRNA RBD3133 ein

Phase 1RBD3133Positive

AI Analysis

Summary

Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals AB successfully submitted a Phase 1 clinical trial application in the EU for RBD3133, an INHBE-directed siRNA therapeutic.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Clinical trial application submitted in EU

Importance:5/10

Sentiment:

0.60

siRNAINHBEEuropean clinical trialPhase 1regulatory submission

Related Companies

$06938.HK

Read the original article

Published by PR Newswire Biotech on October 8, 2026 10:56 PM

Read Original